Disease or Syndrome – Page 4

Lilly’s triple agonist retatrutide posts strongest weight-loss data to date, with unusual sensory skin side effect reported

2 weeks ago talkbio0Tagged Abnormal, aspects of adverse effects, Dysesthesia, Eli, Eli Lilly, Gastric Inhibitory Polypeptide, glucagon, Glucagon-Like Peptide 1, Obesity, Phase III, retatrutide, safety signal, sense of, Therapeutic tactile stimulation, triple agonist, triple hormone receptor agonist, TRIUMPH-4, Weight Loss

Eli Lilly; retatrutide; triple agonist; triple hormone receptor agonist; GLP-1; GIP; glucagon; obesity; weight loss; TRIUMPH-4; Phase III; dysesthesia; abnormal sense of touch; safety signal; side effects

Zealand Pharma and OTR Therapeutics in multi-program strategic collaboration for metabolic diseases

2 weeks ago talkbio0Tagged China, License Agreement, Metabolic Diseases, milestone payments, Obesity, oral small-molecule therapeutics, OXTR gene, Partnership, royalties, strategic collaboration, upfront payment, Zealand Pharma

Zealand Pharma; OTR Therapeutics; strategic collaboration; license agreement; metabolic diseases; obesity; oral small-molecule therapeutics; R&D partnership; China biotech; upfront payment; milestone payments; royalties

Ventus Therapeutics Doses First Patient in Phase 2 Trial of VENT-03, an Oral cGAS Inhibitor, in Lupus

2 weeks ago talkbio0Tagged Autoimmune Diseases, Biological Markers, cardiometabolic, cGAS inhibitor, Clinical Trials, Immunology, inflammaging, interferon pathway, Lupus Erythematosus, Cutaneous, Lupus Vulgaris, oral small molecule, Phase 2 trial, VENT-03, Ventus Therapeutics

Ventus Therapeutics; VENT-03; cGAS inhibitor; Phase 2 trial; lupus; cutaneous lupus erythematosus; autoimmune disease; interferon pathway; biomarkers; oral small molecule; clinical trial; immunology; cardiometabolic; inflammaging

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

2 weeks ago talkbio0Tagged ARIA risk, Binding action, Biological Markers, clinical outcomes, Dental Plaque, oligomer selectivity, Phase 1b Trial, PMN310, PRECISE-AD trial, ProMIS Neurosciences, Toxic Oligomers, vascular deposit binding

ProMIS Neurosciences; PMN310; toxic oligomers; ARIA risk; PRECISE-AD trial; peer-reviewed publication; oligomer selectivity; plaque binding; vascular deposit binding; phase 1b trial; biomarkers; clinical outcomes

Updated Efficacy Data of Ivonescimab Plus Chemotherapy as First-Line Treatment for TNBC at ESMO IO 2025

2 weeks ago talkbio0Tagged AK112 - 308, Breakthrough Therapy Designation, Combined, Complex partial seizures, disease control rate, ESMO IO, First line treatment, Frequency of Responses, HARMONi-BC1, Ivonescimab, PD-1/VEGF bispecific antibody, PD-L1, Pharmacotherapy, Phase 2 Clinical Trials, Progression-Free Survival, safety profile, Subgroup A Nepoviruses, TNBC, Triple Negative Breast Neoplasms, Yidafan

ivonescimab; Yidafan; PD-1/VEGF bispecific antibody; triple-negative breast cancer; TNBC; first-line treatment; ESMO IO 2025; Phase II trial; chemotherapy combination; objective response rate; progression-free survival; disease control rate; PD-L1 CPS subgroups; safety profile; Breakthrough Therapy Designation; HARMONi-BC1; AK112-308

Spotlight On: It’s Raining AI Devices as Regulatory Storm Reshapes Digital Health

2 weeks ago talkbio0Tagged 2025, Accountability, AI-enabled, clinical oversight, digital health regulation, digital mental health devices, draft guidance, EU, EU AI Act health, Generative AI, Health care facility, Medical Devices, Regulation, Software as a Medical Device, United States Food and Drug Administration

AI-enabled medical devices; digital health regulation 2025; FDA AI draft guidance; EU AI Act health; generative AI in healthcare; SaMD regulation; clinical oversight of AI; AI accountability in healthcare; digital mental health devices

Recent advances in AI for antimicrobial resistance (AMR) prevention and control

2 weeks ago talkbio0Tagged AI antibiotic discovery, Antibiotics, Antimicrobial Resistance, Diagnostics, Generative AI, GPR182 gene, Health care facility, Machine Learning, Phage Therapy, Stewardship, surveillance aspects

antimicrobial resistance; AI in healthcare; machine learning; antibiotic stewardship; AI antibiotic discovery; phage therapy; rapid diagnostics; AMR surveillance; generative AI

UK cuts 2026 new-medicine rebate rate to 14.5% under VPAG

2 weeks ago talkbio0Tagged branded medicines, clawback rate, Drug Industry, drug price, Growth, Nance-Horan syndrome, rebate rate, United Kingdom, valproic acid glucuronide, Voluntary Scheme

United Kingdom; VPAG; Voluntary Scheme for Branded Medicines Pricing Access and Growth; rebate rate; clawback rate; new medicines; NHS; drug pricing; pharmaceutical industry; 2026

FDA Broadens COVID-19 Vaccine Safety Probe to Adults Under New Health Leadership

2 weeks ago talkbio0Tagged Adult, COVID19 (disease), Moderna, Myocarditis, Pfizer, public trust, safety review, United States Food and Drug Administration, vaccine deaths, Vaccines

FDA; COVID-19 vaccines; safety review; adults; Robert F. Kennedy Jr.; vaccine deaths; public trust; Pfizer; Moderna; myocarditis

J&J-backed Cellular Origins raises $40M for cell therapy manufacturing

2 weeks ago talkbio0Tagged cell therapy manufacturing, Cellular Origins, Constellation platform, cyclic adenosine-5'-trimetaphosphate, Groups, Johnson & Johnson, Manufacturing, Purpura, Thrombotic Thrombocytopenic, robotic automation

Cellular Origins; Johnson & Johnson; Series A; $40 million; cell therapy manufacturing; Constellation platform; robotic automation; ATMP; TTP Group; scalable manufacturing